User menu

Good Tolerance to Full-Dose Crizotinib in a Patient with Anaplastic Lymphoma Receptor Tyrosine Kinase-Rearranged Lung Adenocarcinoma and Preexisting Renal Impairment.

Bibliographic reference Rosoux, Adeline ; Duplaquet, Fabrice ; Ocak, Sebahat. Good Tolerance to Full-Dose Crizotinib in a Patient with Anaplastic Lymphoma Receptor Tyrosine Kinase-Rearranged Lung Adenocarcinoma and Preexisting Renal Impairment.. In: Case Reports in Oncology, Vol. 10, no.2, p. 447-451 (2017)
Permanent URL http://hdl.handle.net/2078.1/187594
  1. Camidge D Ross, Bang Yung-Jue, Kwak Eunice L, Iafrate A John, Varella-Garcia Marileila, Fox Stephen B, Riely Gregory J, Solomon Benjamin, Ou Sai-Hong I, Kim Dong-Wan, Salgia Ravi, Fidias Panagiotis, Engelman Jeffrey A, Gandhi Leena, Jänne Pasi A, Costa Daniel B, Shapiro Geoffrey I, LoRusso Patricia, Ruffner Katherine, Stephenson Patricia, Tang Yiyun, Wilner Keith, Clark Jeffrey W, Shaw Alice T, Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study, 10.1016/s1470-2045(12)70344-3
  2. Kwak Eunice L., Bang Yung-Jue, Camidge D. Ross, Shaw Alice T., Solomon Benjamin, Maki Robert G., Ou Sai-Hong I., Dezube Bruce J., Jänne Pasi A., Costa Daniel B., Varella-Garcia Marileila, Kim Woo-Ho, Lynch Thomas J., Fidias Panos, Stubbs Hannah, Engelman Jeffrey A., Sequist Lecia V., Tan WeiWei, Gandhi Leena, Mino-Kenudson Mari, Wei Greg C., Shreeve S. Martin, Ratain Mark J., Settleman Jeffrey, Christensen James G., Haber Daniel A., Wilner Keith, Salgia Ravi, Shapiro Geoffrey I., Clark Jeffrey W., Iafrate A. John, Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer, 10.1056/nejmoa1006448
  3. Shaw Alice T., Kim Dong-Wan, Nakagawa Kazuhiko, Seto Takashi, Crinó Lucio, Ahn Myung-Ju, De Pas Tommaso, Besse Benjamin, Solomon Benjamin J., Blackhall Fiona, Wu Yi-Long, Thomas Michael, O'Byrne Kenneth J., Moro-Sibilot Denis, Camidge D. Ross, Mok Tony, Hirsh Vera, Riely Gregory J., Iyer Shrividya, Tassell Vanessa, Polli Anna, Wilner Keith D., Jänne Pasi A., Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer, 10.1056/nejmoa1214886
  4. Solomon Benjamin J., Mok Tony, Kim Dong-Wan, Wu Yi-Long, Nakagawa Kazuhiko, Mekhail Tarek, Felip Enriqueta, Cappuzzo Federico, Paolini Jolanda, Usari Tiziana, Iyer Shrividya, Reisman Arlene, Wilner Keith D., Tursi Jennifer, Blackhall Fiona, First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer, 10.1056/nejmoa1408440
  5. Brosnan Evelyn M., Weickhardt Andrew J., Lu Xian, Maxon Delee A., Barón Anna E., Chonchol Michel, Camidge D. Ross, Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib : eGFR and Crizotinib, 10.1002/cncr.28478
  6. Gastaud Lauris, Ambrosetti Damien, Otto Josiane, Marquette Charles-Hugo, Coutts Michael, Hofman Paul, Esnault Vincent, Favre Guillaume, Acute kidney injury following crizotinib administration for non-small-cell lung carcinoma, 10.1016/j.lungcan.2013.08.007
  7. Martín Martorell Paloma, Huerta Alvaro Marisol, Solís Salguero Miguel A., Insa Molla Amelia, Crizotinib and renal insufficiency: A case report and review of the literature, 10.1016/j.lungcan.2014.03.001
  8. Camidge D. Ross, Brosnan Evelyn M., DeSilva Chamath, Koo Phillip J., Chonchol Michel, Crizotinib Effects on Creatinine and Non-Creatinine–Based Measures of Glomerular Filtration Rate, 10.1097/jto.0000000000000321